No Data
Earnings Preview: LUCD to Report Financial Results Pre-market on November 13
$Lucid Diagnostics(LUCD.US)$ is scheduled to release its financial results pre-market on November 13 ET. Earnings PreviewAnalysts estimate $Lucid Diagnostics(LUCD.US)$ to post revenue of USD1.14M
Lucid Diagnostics Shares Are Trading Higher After the Company Announced Its ESOGUARD BE-1 Clinical Validation Study of Precancer Testing Was Accepted for Publication.
Express News | Lucid Diagnostics' Esoguard Be-1 Prospective Multicenter Clinical Validation Study of Esoguard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Press Release: Lucid Diagnostics Expands Direct Contracting Initiative With Multiple Programs Focused on Near-Term Revenue Drivers
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
No Data
No Data